Antagonistes du récepteur de type 1 de l'angiotensine-II : Questions médicales fréquentes
Nom anglais: Angiotensin II Type 1 Receptor Blockers
Descriptor UI:D047228
Tree Number:D27.505.519.162.500
Termes MeSH sélectionnés :
Early Detection of Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antagonistes du récepteur de type 1 de l'angiotensine-II : Questions médicales les plus fréquentes",
"headline": "Antagonistes du récepteur de type 1 de l'angiotensine-II : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antagonistes du récepteur de type 1 de l'angiotensine-II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-21",
"dateModified": "2025-04-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antagonistes du récepteur de type 1 de l'angiotensine-II"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antagonistes des récepteurs aux angiotensines",
"url": "https://questionsmedicales.fr/mesh/D057911",
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes des récepteurs aux angiotensines",
"code": {
"@type": "MedicalCode",
"code": "D057911",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.162"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes du récepteur de type 1 de l'angiotensine-II",
"alternateName": "Angiotensin II Type 1 Receptor Blockers",
"code": {
"@type": "MedicalCode",
"code": "D047228",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Tadashi Namisaki",
"url": "https://questionsmedicales.fr/author/Tadashi%20Namisaki",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan. tadashin@naramed-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Kosuke Kaji",
"url": "https://questionsmedicales.fr/author/Kosuke%20Kaji",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan."
}
},
{
"@type": "Person",
"name": "Naotaka Shimozato",
"url": "https://questionsmedicales.fr/author/Naotaka%20Shimozato",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan."
}
},
{
"@type": "Person",
"name": "Yukihisa Fujinaga",
"url": "https://questionsmedicales.fr/author/Yukihisa%20Fujinaga",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Modelled mortality benefits of multi-cancer early detection screening in England.",
"datePublished": "2023-04-25",
"url": "https://questionsmedicales.fr/article/37185463",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41416-023-02243-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of early detection on cancer curability: A modified Delphi panel study.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36542647",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0279227"
}
},
{
"@type": "ScholarlyArticle",
"name": "Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.",
"datePublished": "2024-10-15",
"url": "https://questionsmedicales.fr/article/39456841",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms252011060"
}
},
{
"@type": "ScholarlyArticle",
"name": "REPRESENT recommendations: improving inclusion and trust in cancer early detection research.",
"datePublished": "2023-09-09",
"url": "https://questionsmedicales.fr/article/37689805",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41416-023-02414-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of cell-free DNA approaches for multi-cancer early detection.",
"datePublished": "2022-11-17",
"url": "https://questionsmedicales.fr/article/36400018",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ccell.2022.10.022"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antagonistes des récepteurs aux angiotensines",
"item": "https://questionsmedicales.fr/mesh/D057911"
},
{
"@type": "ListItem",
"position": 6,
"name": "Antagonistes du récepteur de type 1 de l'angiotensine-II",
"item": "https://questionsmedicales.fr/mesh/D047228"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antagonistes du récepteur de type 1 de l'angiotensine-II - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Comment diagnostiquer une hypertension ?\nQuels tests pour évaluer l'efficacité des ARA ?\nQuels signes indiquent une insuffisance cardiaque ?\nComment évaluer les effets secondaires des ARA ?\nQuand faire un ECG chez un patient sous ARA ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Quels symptômes nécessitent un avis médical urgent ?\nQuels effets secondaires courants des ARA ?\nComment reconnaître une hypotension ?\nQuels symptômes d'une réaction allergique aux ARA ?\nQuels signes d'une hyperkaliémie ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Comment prévenir l'hypertension ?\nLe tabagisme influence-t-il l'hypertension ?\nL'alcool affecte-t-il la pression artérielle ?\nComment le stress impacte-t-il la santé cardiaque ?\nQuels aliments éviter pour contrôler la pression ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Comment fonctionnent les ARA ?\nQuels sont les ARA les plus prescrits ?\nQuand débuter un traitement par ARA ?\nLes ARA sont-ils sûrs pendant la grossesse ?\nComment ajuster la dose d'ARA ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Quelles sont les complications de l'hypertension ?\nComment l'hypertension affecte-t-elle les reins ?\nQuels risques d'AVC liés à l'hypertension ?\nL'hypertension peut-elle causer des problèmes oculaires ?\nQuels effets de l'hypertension sur le cœur ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antagonistes du récepteur de type 1 de l'angiotensine-II",
"description": "Quels sont les principaux facteurs de risque d'hypertension ?\nLe diabète influence-t-il l'hypertension ?\nL'hérédité joue-t-elle un rôle dans l'hypertension ?\nLe manque d'exercice est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une hypertension ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension est diagnostiquée par des mesures répétées de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'efficacité des ARA ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de pression artérielle et des analyses sanguines pour surveiller les électrolytes sont effectués."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une insuffisance cardiaque ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Essoufflement, fatigue, œdèmes et palpitations peuvent indiquer une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires des ARA ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier des symptômes et des tests sanguins pour les électrolytes est nécessaire."
}
},
{
"@type": "Question",
"name": "Quand faire un ECG chez un patient sous ARA ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un ECG est recommandé si le patient présente des symptômes cardiaques ou des anomalies de pression."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un avis médical urgent ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des difficultés respiratoires ou des évanouissements doivent être évalués."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires courants des ARA ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des vertiges, des maux de tête et des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hypotension ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des étourdissements, une vision floue et une fatigue excessive."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une réaction allergique aux ARA ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Quels signes d'une hyperkaliémie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des palpitations, une faiblesse musculaire et des picotements peuvent signaler une hyperkaliémie."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypertension ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et la gestion du stress aident à prévenir l'hypertension."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il l'hypertension ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque d'hypertension et de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'alcool affecte-t-il la pression artérielle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consommation excessive d'alcool peut entraîner une augmentation de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Comment le stress impacte-t-il la santé cardiaque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut contribuer à l'hypertension et à d'autres problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quels aliments éviter pour contrôler la pression ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé d'éviter les aliments riches en sodium et en graisses saturées."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les ARA ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les ARA bloquent les récepteurs de l'angiotensine-II, réduisant ainsi la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels sont les ARA les plus prescrits ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les ARA courants incluent le losartan, le valsartan et l'irbésartan."
}
},
{
"@type": "Question",
"name": "Quand débuter un traitement par ARA ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement par ARA est débuté lorsque d'autres antihypertenseurs sont inefficaces ou mal tolérés."
}
},
{
"@type": "Question",
"name": "Les ARA sont-ils sûrs pendant la grossesse ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les ARA sont généralement contre-indiqués pendant la grossesse en raison de risques pour le fœtus."
}
},
{
"@type": "Question",
"name": "Comment ajuster la dose d'ARA ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dose est ajustée en fonction de la réponse du patient et des effets secondaires observés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de l'hypertension ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les maladies cardiaques, les AVC et les lésions rénales."
}
},
{
"@type": "Question",
"name": "Comment l'hypertension affecte-t-elle les reins ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension peut endommager les vaisseaux sanguins des reins, entraînant une insuffisance rénale."
}
},
{
"@type": "Question",
"name": "Quels risques d'AVC liés à l'hypertension ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension augmente le risque d'accident vasculaire cérébral ischémique et hémorragique."
}
},
{
"@type": "Question",
"name": "L'hypertension peut-elle causer des problèmes oculaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des lésions rétiniennes et des problèmes de vision."
}
},
{
"@type": "Question",
"name": "Quels effets de l'hypertension sur le cœur ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une hypertrophie du cœur, des arythmies et une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'hypertension ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'obésité, le tabagisme et une alimentation riche en sodium."
}
},
{
"@type": "Question",
"name": "Le diabète influence-t-il l'hypertension ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète augmente le risque d'hypertension et de complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans l'hypertension ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'hypertension augmentent le risque individuel."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire contribue à l'augmentation de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Le stress chronique est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à l'hypertension et à d'autres problèmes de santé."
}
}
]
}
]
}
Screening programmes utilising blood-based multi-cancer early detection (MCED) tests, which can detect a shared cancer signal from any site in the body with a single, low false-positive rate, could re...
A natural history ('interception') model of cancer was previously used to characterise potential benefits of MCED screening (based on published performance of an MCED test). We built upon this using a...
Estimated late-stage and mortality reductions were robust to a range of assumptions. With the least favourable dwell (sojourn) time and cfDNA status hazard ratio assumptions, we estimated, among 100,0...
Realising the potential benefits of MCED tests could substantially reduce late-stage cancer diagnoses and mortality....
Expert consensus on the potential benefits of early cancer detection does not exist for most cancer types. We convened 10 practicing oncologists using a RAND/UCLA modified Delphi panel to evaluate whi...
Colorectal cancer (CRC) remains the second most common cause of cancer-related mortality worldwide, necessitating advancements in early detection and innovative treatment strategies. MicroRNAs (miRNAs...
Detecting cancer early is essential to improving cancer outcomes. Minoritized groups remain underrepresented in early detection cancer research, which means that findings and interventions are not gen...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining cl...
Globally, among all women, the most frequently detected and diagnosed and the most lethal type of cancer is breast cancer (BC). In particular, bone is one of the most frequent distant metastases 24in ...
GSE55715, GSE103357, and GSE146661 gene expression profiling data were downloaded from the GEO database. There was 14 breast cancer with bone metastasis samples and 8 breast cancer tissue samples. GEO...
By GO enrichment analysis, 143 DEGs were enriched in the following GO terms: extracellular structure organization, extracellular matrix organization, leukocyte migration class II protein complex, coll...
2 abnormally expressed hub genes could play a pivotal role in the breast cancer with bone metastasis by affecting bone homeostasis imbalance in the bone microenvironment....
Seemingly normal tissues progressively become populated by mutant clones over time. Most of these clones bear mutations in well-known cancer genes but only rarely do they transform into cancer. This p...
We analyzed recent mutational screens of healthy and cancer-free diseased tissues to compare somatic drivers and the causes of somatic variation across tissues. We then reviewed the mechanisms of clon...
The extent of somatic variation is highly variable across tissues and depends on intrinsic features, such as tissue architecture and turnover, as well as the exposure to endogenous and exogenous insul...
Somatic variation and the factors governing homeostasis of normal tissues should be taken into account when devising strategies for cancer prevention and early detection....
The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer s...
The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane D...
The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsy, and biopsy techni...
Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a bas...
Lung cancer is a major global health concern with a low survival rate, often due to late-stage diagnosis. Liquid biopsy offers a non-invasive approach to cancer detection and monitoring, utilizing var...
The present study is a systematic review of the evaluation of screening programs as a strategy for early detection of oral cancer. The aim of this study was to assess whether screening through visual ...